| ASTELLAS-PHARMA-INC |
ASTELLAS-PHARMA-INC |
92%
|
The Company recognized revenue as follows: Three Months Ended March 31, 2026 2025 (in thousands) Astellas Pharma Inc. ("Astellas") $ 14,508 $ 16,879 |
| BX |
Blackstone Inc. |
90%
|
Reciprocal relationship from BX graph: Reciprocal relationship from STRO graph: Reciprocal relationship from BX graph: Reciprocal relationship from STRO graph: In June 2023, we entered into a purchas… |
| BX |
Blackstone Inc. |
90%
|
In June 2023, we entered into a purchase and sale agreement with Blackstone, or the Blackstone Agreement, to sell to Blackstone a revenue interest in our 4% royalty on potential future sales of Vaxcy… |
| VAXCYTE |
VAXCYTE |
90%
|
In November 2023, or the Exercise Date, Vaxcyte exercised the Option by submitting written notice thereof to us and concurrently paid us $50.0 million in cash as the first of two installment payments… |
| TASLY |
TASLY |
85%
|
In December 2021, we entered into the Tasly License Agreement with Tasly to grant an exclusive license to develop and commercialize STRO-002 in Greater China. |
| MYGN |
Myriad Genetics, Inc. |
72%
|
n of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not re… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from STRO graph: n of up to five years for a patent covering an approved product as compensation for effective patent term lost during… |
| PCVX |
Vaxcyte, Inc. |
72%
|
Reciprocal relationship from PCVX graph: rrently expect or change their requirements regarding the data required to support a marketing application; • the costs of establishing additional manufacturi… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from STRO graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from STRO graph: n of up to five years for a paten… |
| SNYNF |
Sanofi |
72%
|
n of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not re… |
| ALEMANY-PLAZA-LLC |
ALEMANY-PLAZA-LLC |
62%
|
, at a price of approximately $ 51.79 per share, in accordance with the terms set forth in a certain investment agreement by and between the Company and Ipsen USA dated March 29, 2024 (the “Ipsen Inv… |
| CELLECT-LLC |
CELLECT-LLC |
62%
|
n of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not re… |
| FIVE-PRIME-THERAPEUTICS-INC |
FIVE-PRIME-THERAPEUTICS-INC |
62%
|
(38,484 ) $ (75,968 ) $ 37,484 (49 )% *Percentage not meaningful Revenue We have recognized revenue as follows during the indicated periods: Three Months Ended March 31, 2026 2025 Change Change (%) (… |
| IPSEN-BIOPHARMACEUTICALS-INC |
IPSEN-BIOPHARMACEUTICALS-INC |
62%
|
ricing is based on an agreed upon cost-plus arrangement. During 2020, upon Vaxcyte’s request and their agreement to reimburse the related costs, the Company entered into agreements with third-party c… |
| IPSEN-BIOPHARMA-INC |
IPSEN-BIOPHARMA-INC |
62%
|
dit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial stateme… |
| LEERINK-PARTNERS-LLC |
LEERINK-PARTNERS-LLC |
62%
|
(38,484 ) $ (75,968 ) $ 37,484 (49 )% *Percentage not meaningful Revenue We have recognized revenue as follows during the indicated periods: Three Months Ended March 31, 2026 2025 Change Change (%) (… |
| SAN-CARLOS-ASSET-GROUP |
SAN-CARLOS-ASSET-GROUP |
62%
|
rophylaxis of any disease that is not caused by an infectious pathogen, including cancer. In June 2023, Blackstone made an upfront payment of $ 140.0 million to the Company and will also pay up to an… |
| USA-LLC |
USA-LLC |
62%
|
(38,484 ) $ (75,968 ) $ 37,484 (49 )% *Percentage not meaningful Revenue We have recognized revenue as follows during the indicated periods: Three Months Ended March 31, 2026 2025 Change Change (%) (… |
